Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISIONARY: Targeted Therapy for Refractory Digestive Cancers
NCT04584008Active, not recruiting
- Sponsor
- Peking University
- Start
- Sep 2020
- Primary completion
- Nov 2024
- Countries
- 1
01
Overview
Open-label trial in biliary tract cancer (BTC), gastric cancer (GC), Esophageal Squamous Cell Carcinoma (ESCC) and 5 more, sponsored by Peking University. Started Sep 2020; status: active, not recruiting.
02
Conditions
biliary tract cancer (BTC)gastric cancer (GC)Esophageal Squamous Cell Carcinoma (ESCC)colorectal cancer (CRC)gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT04584008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04584008.